Repligen Co. (NASDAQ:RGEN) Shares Acquired by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC increased its position in Repligen Co. (NASDAQ:RGEN) by 133.2% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 4,009 shares of the biotechnology company’s stock after purchasing an additional 2,290 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Repligen were worth $597,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Andra AP fonden purchased a new position in shares of Repligen during the second quarter worth approximately $25,000. Lazard Asset Management LLC boosted its stake in Repligen by 206.1% during the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 136 shares during the period. UMB Bank n.a. grew its position in Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 127 shares during the last quarter. Finally, International Assets Investment Management LLC acquired a new stake in shares of Repligen during the second quarter worth about $33,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. UBS Group dropped their price target on Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Royal Bank of Canada restated an “outperform” rating and set a $205.00 price target on shares of Repligen in a research note on Thursday, September 26th. Stephens reiterated an “overweight” rating and issued a $170.00 price objective on shares of Repligen in a research report on Tuesday, July 30th. Benchmark restated a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, July 31st. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $190.25.

Insiders Place Their Bets

In other news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares in the company, valued at approximately $20,328,540.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.20% of the stock is currently owned by company insiders.

Repligen Stock Performance

NASDAQ:RGEN opened at $143.88 on Friday. The firm’s fifty day simple moving average is $141.77 and its 200-day simple moving average is $145.51. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26. The stock has a market cap of $8.06 billion, a PE ratio of -3,596.10, a price-to-earnings-growth ratio of 4.01 and a beta of 0.96. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $211.13.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.